Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31092643 | 1.00 | MEN1 (0.33) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL23912632 | 0.83 | TP53 (0.32) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30790707 | 0.80 | KMT2A (0.43) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31092635 | 0.78 | ITGB2 (0.41) | ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL23904934 | 0.78 | ITGB2 (0.41) | ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL30790754 | 0.77 | HRH3 (0.34) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30790709 | 0.75 | HRH3 (0.50) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL32677965 | 0.75 | CHRM4 (0.35) | MEN1KMT2ASMN1; SMN2MAPTCHRM4 | |
| SCHEMBL32677968 | 0.75 | CHRM4 (0.35) | MEN1KMT2ASMN1; SMN2MAPTCHRM4 | |
| SCHEMBL22042496 | 0.74 | TRPC6 (0.32) | ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-13 | — | — | US | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| EP-3892278-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-10-13 | — | — | EP | disclosed |
| CN-113164481-A | Cycloalkane-1, 3-diamine derivatives | 第一三共株式会社 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020116662-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | 第一三共株式会社 | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | MEN1 2/4885KMT2A 23/4885SMN1; SMN2 1327/4885 |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | MEN1 2/4885KMT2A 23/4885SMN1; SMN2 1327/4885 |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | MEN1 2/4885KMT2A 23/4885SMN1; SMN2 1327/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | MEN1 15/4885KMT2A 23/4885SMN1; SMN2 1678/4885 |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | MEN1 2/4885KMT2A 23/4885SMN1; SMN2 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.